EGFR and cancer: In addition to the well-documented resistance mechanisms against EGFR and PI3K pathway inhibitors, such as mutations [4,5] and the intricate crosstalk with other pivotal signaling pathways [6,7], drug efflux pumps might diminish the effectiveness of MTX-211 by reducing its intracellular concentrations in human cancer cells.